Diabetes Discourse

Ms. Deborah Hinnen, an advanced practice nurse and certified diabetes educator at the University of Colorado Health in Colorado Springs sits down with Dr. Charles Turck to discuss hypoglycemia risk factors and treatment protocols according to the ADA guidelines.

Tune in to hear primary care physician and endocrinologist Dr. Rozalina G. McCoy discuss how we can talk to our diabetes patients about hypoglycemia and what we need to consider when treating older patients who are experiencing hypoglycemia emergency.

Since patients with type 2 diabetes on multiple daily injections of insulin are at high risk of hypoglycemia, Dr. Charles Turck discusses essential counseling strategies for these high-risk patients with Dr. Alexis Mckee, an endocrinologist and Assistant Professor of Medicine at Washington School of Medicine in St. Louis, Missouri. Together, they’ll review how we can help patients avoid, manage, and treat hypoglycemia emergencies.

When treating type 1 diabetes, should we be focusing on disease prevention rather than reversal? Dr. John Anderson takes a look at prevention tactics for type 1 diabetes progression with Dr. Raghu Mirmira, a Professor of Medicine and the Director of the Translational Research Center at the University of Chicago.

Experts in the immunopathology of type 1 diabetes discuss the epidemiology, non-genetic and genetic risk factors, and progression from preclinical to clinical stages of this disease. The discussion will emphasize the breakdown of immune tolerance that precedes type 1 diabetes and the subsequent pathogenetic role of islet autoantibodies responsible for its clinical manifestations.

How is technology like continuous glucose monitors impacting the way we care for patients with diabetes, especially amid the COVID-19 pandemic? To learn more about the technological advancements in diabetes care, Dr. Carol Wysham speaks with Dr. Irl Hirsch, a Professor in Diabetes Treatment and Teaching Chair at the University of Washington School of Medicine in Seattle, Washington.

Why was there so much discordance between some patients’ GMI and their measured A1C? That’s the exact question Dr. Irl Hirsch from the University of Washington School of Medicine asked and explored in a paper he recently co-authored. And now Dr. Hirsch is here to share his findings.

SGLT-2 inhibitors have been authorized for diabetic patients in Europe, but is it close to receiving FDA approval in the U.S.? Dr. Anne Peters of USC speaks with Dr. John Buse about SGLT-2 inhibitors and considerations for diabetic ketoacidosis, heart failure, and chronic kidney disease.

It can be tempting for patients to undermine the seriousness of diabetes. But in recognition of Diabetes Alert Day, Dr. John Buse explains why we need to set the record straight.

How early should we start screening for diabetes, and what tools are available to us? In recognition of Diabetes Alert Day, Dr. John Buse reviews the current screening tests and recommendations for those who are at risk of diabetes.